Avalo Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Avalo Therapeutics (AVTX).

Price Target Range — 9 Quarters

Analyst Consensus — 15 Analysts

1S.Buy

14Buy

Consensus RatingBuy# Analysts15Avg. Consensus PT$40Upside to Avg. PT+194.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 7, 2026	Guggenheim	Yatin Suneja	PT Cut	Buy	$50→$48
Aug 7, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$35→$30
Jul 6, 2026	Leerink Partners	Thomas Smith	Initiate	Outperform	$38
Jun 16, 2026	BTIG	Julian Harrison	Maintained	Buy	$58
Jun 12, 2026	B of A Securities	Alec Stranahan	Initiate	Buy	$35
May 14, 2026	Citizens	Jason N. Butler	PT Cut	Market Outperform	$62→$55
May 14, 2026	Wedbush	Robert Driscoll	PT Cut	Outperform	$40→$34
May 14, 2026	Mizuho	Joseph Catanzaro	PT Raise	Outperform	$39→$45
May 14, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$40→$35
May 11, 2026	Piper Sandler	Yasmeen Rahimi	PT Raise	Overweight	$48→$60
May 6, 2026	Citizens	Jason N. Butler	PT Raise	Market Outperform	$52→$62
May 6, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$29→$40
May 6, 2026	BTIG	Julian Harrison	PT Raise	Buy	$40→$58
Apr 13, 2026	BTIG	Julian Harrison	Maintained	Buy	$40
Apr 9, 2026	Wolfe Research	Andy Chen	Initiate	Outperform	$48
Apr 6, 2026	Citizens	Jason Butler	Initiate	Market Outperform	$52
Mar 25, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$25→$40
Mar 24, 2026	BTIG	Julian Harrison	Maintained	Buy	$40
Feb 2, 2026	Guggenheim	Yatin Suneja	Initiate	Buy	$50
Jan 15, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$25

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Avalo Therapeutics, Lowers Price Target to $48

Guggenheim analyst Yatin Suneja maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $50 to $48.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Lowers Price Target to $30

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $35 to $30.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Avalo Therapeutics with Outperform Rating, Announces Price Target of $38

Leerink Partners analyst Thomas Smith initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Outperform rating and announces Price Target of $38.

Benzinga Newsdesk

This ICU Medical Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed outlook on top names. Find all rating changes on Benzinga's analyst ratings page. See analyst views on ICUI, BDSX,.

Avi Kapoor

This FormFactor Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday

Wall Street analysts upgraded EDU, MKTX, and FORM stocks. Check out their ratings on Benzinga's analyst ratings page before buying EDU.

Avi Kapoor

This Sailpoint Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday

Wall Street analysts downgrade ADBE and SAIL, cutting price targets. Check other analysts' views on these stocks. Photo via Shutterstock.

Avi Kapoor

Avalo Therapeutics Inc

Avalo Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Avalo Therapeutics, Lowers Price Target to $48

PRO
HC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Lowers Price Target to $30

PRO
Leerink Partners Initiates Coverage On Avalo Therapeutics with Outperform Rating, Announces Price Target of $38

This ICU Medical Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

This FormFactor Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday

This Sailpoint Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday

People Also Watch

People Also Watch

Avalo Therapeutics Inc

Avalo Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Maintains Buy on Avalo Therapeutics, Lowers Price Target to $48

PROHC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Lowers Price Target to $30

PROLeerink Partners Initiates Coverage On Avalo Therapeutics with Outperform Rating, Announces Price Target of $38

This ICU Medical Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

This FormFactor Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday

This Sailpoint Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday

People Also Watch

People Also Watch

PRO
Guggenheim Maintains Buy on Avalo Therapeutics, Lowers Price Target to $48

PRO
HC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Lowers Price Target to $30

PRO
Leerink Partners Initiates Coverage On Avalo Therapeutics with Outperform Rating, Announces Price Target of $38